Results 61 to 70 of about 408 (149)

PD‐1‐Cis IL‐2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1‐IL2v)

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 2128-2138, December 2025.
ABSTRACT Binding in cis‐configuration to the PD‐1 receptor (PD‐1) and IL‐2βγ receptor (IL‐2Rβγ) has been shown to lead to differentiation of CD8 T cells to better effectors, which is anticipated to drive efficacy of the immune‐targeted cytokine eciskafusp alfa, or PD1‐IL2v.
Lucy G. Hutchinson, Thomas D. Lewin, Laura Lauener, Meret Martin‐Facklam, Merlind Muecke, Volker Teichgraeber, Laura Codarri Deak   +6 more
wiley   +1 more source

Anti-CD70-IFN-γ immunocytokines display species-specific antiviral activity.

, 2013
Murine (RenCa) or human (Caki-1) RCC cells were pre-treated for 16 h with anti-CD70 immunocytokines bearing either murine (m) or human (h) IFN-γ (‘Anti-CD70 fusion’, 50 ng/ml).
Peirong Chen (403320), Shoko Nogusa (347948), Heidi Simmons (403323), Gregory P. Adams (269450), Siddharth Balachandran (66976), Calvin Shaller (403322), Suraj Peri (70543), Roshan J. Thapa (403321)   +7 more
core   +1 more source

Cytokine Engineering Approaches for Regenerative Medicine

Advanced Therapeutics, Volume 8, Issue 9, September 2025.
Engineered cytokines represent a powerful strategy to promote tissue repair and regeneration by precisely modulating immune responses. This review highlights recent advances in cytokine engineering, including strategies to enhance half‐life, improve tissue and cell targeting, and control receptor signaling.
Shiyi Li, Wenhao You, Mikaël M. Martino
wiley   +1 more source

Fine-tuning the immune response against cancer with antibody-cytokine fusion proteins

, 2023
Antibody-cytokine fusion proteins, also known as immunocytokines, comprise a novel class of biopharmaceuticals designed to localize immunomodulatory agents toward the tumor site and stimulate local immune cells to activate an anticancer response.
Gatto, Matías Iván, Ferrero, Sol, Helguera, Gustavo Fernando, Sol Ferrero, Gustavo Helguera, Matías Gatto   +5 more
core   +1 more source

3D‐Printing of Electroconductive MXene‐Based Micro‐Meshes in a Biomimetic Hyaluronic Acid‐Based Scaffold Directs and Enhances Electrical Stimulation for Neural Repair Applications

Advanced Science, Volume 12, Issue 34, September 11, 2025.
This study combined microscale 3D‐printing with 2D Ti3C2Tx MXene nanosheets to produce electroconductive microfibrous micro‐meshes. By embedding these MXene‐functionalized micro‐meshes within a growth‐supportive macroporous extracellular matrix (ECM)‐based biomaterial, multifunctional biomimetic MXene‐ECM scaffolds were developed.
Ian Woods, Dahnan Spurling, Sandra Sunil, Anne Marie O'Callaghan, Jack Maughan, Javier Gutierrez‐Gonzalez, Tara K. McGuire, Liam Leahy, Adrian Dervan, Valeria Nicolosi, Fergal J. O'Brien   +10 more
wiley   +1 more source

Universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44+ CD8+ T cells in tumor-draining lymph nodes to enhance antitumor immunity

Journal for ImmunoTherapy of Cancer
Background Immunocytokines targeting immune checkpoints have shown great potential in overcoming resistance to immune checkpoint blockade (ICB), making them a major focus of development in recent years.
Wei Li, Ying Qin, Zejian Wang, Luyao Song, Gen Qi, Wenqiang Shi, Qiongya Zeng, Zilan Song, Ao Zhang, Huili Lu   +9 more
doaj   +1 more source

Fibronectin Fibers Progressively Lose Their Tension in Invasive Human Breast Carcinoma while Being Tensed in DCIS and Healthy Breast Tissue

Advanced Science, Volume 12, Issue 31, August 21, 2025.
Extracellular matrix remodeling is crucial in cancer progression. Using a peptide to probe the tension of ECM fibers, it was found that Fibronectin fibers gradually lose tension as human breast carcinoma progresses, while their tension is maintained in ductal carcinoma in situ (DCIS), the non‐invasive precursor of breast cancer. This loss of tension is
Arnaud Miéville, Charlotte M. Fonta, Cornelia Leo, Lucine Christe, Jörg Goldhahn, Gad Singer, Viola Vogel   +6 more
wiley   +1 more source

Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes

Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 74-79, July 2025.
Oncology dose optimization during the era of chemotherapy focused on identifying the maximum tolerated dose (MTD) for registrational trials, often resulting in significant toxicity. The advent of molecular targeted drugs and immunotherapies offers the potential to achieve similar efficacy with lower doses and fewer side effects, as maximal efficacy is ...
Jiawen Zhu, Amy Schroeder, Sabine Frank, Christophe Boetsch, Candice Jamois, Nastya Kassir, Koorosh Korfi, Elizabeth Punnoose, Anjali Vaze, Peter Trask, Pritti Gosai, Jane Fridlyand, Chunze Li   +12 more
wiley   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets

MedComm, Volume 6, Issue 7, July 2025.
Cancer‐associated fibroblasts (CAFs) arise from normal fibroblasts in response to various tumor microenvironmental signals, including cytokines such as TGF‐β and IL‐6, paracrine factors like PDGFs, Notch signaling, extracellular vesicles, as well as aging, inflammation, hypoxia, oxidative stress, and increased extracellular matrix (ECM) stiffness. Upon
Yutao Li, Qingyun Liu, Xilin Jing, Yuqi Wang, Xiaohua Jia, Xing Yang, Kezhong Chen   +6 more
wiley   +1 more source